Meanwhile, pan-cancer analysis based on the TIMER2 database41 (http://timer.cistrome.org) showed that NUPR1 had an inconsistent expression trend in different tumors, the expression of NUPR1 was decreased in bladder cancer, colon cancer, lung adenocarcinoma, prostate cancer, and other tumors. This evidence concerns the gene NUPR1 and prostate carcinoma.